Bank of America’s Annovis Bio ANVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-207
Closed -$716 5749
2025
Q4
$716 Buy
207
+62
+43% +$186 ﹤0.01% 6510
2025
Q3
$300 Sell
145
-10
-6% -$25 ﹤0.01% 7670
2025
Q2
$336 Buy
155
+19
+14% +$37 ﹤0.01% 7741
2025
Q1
$204 Buy
136
+52
+62% +$159 ﹤0.01% 7685
2024
Q4
$423 Sell
84
-5,996
-99% -$43.4K ﹤0.01% 7439
2024
Q3
$49K Buy
6,080
+1,015
+20% +$9.51K ﹤0.01% 6549
2024
Q2
$29.2K Sell
5,065
-449
-8% -$3.64K ﹤0.01% 6650
2024
Q1
$65.6K Buy
5,514
+2,245
+69% +$24.5K ﹤0.01% 6429
2023
Q4
$61.1K Buy
3,269
+3,092
+1,747% +$27.4K ﹤0.01% 6545
2023
Q3
$1.68K Hold
177
﹤0.01% 7172
2023
Q2
$2.53K Buy
+177
New +$2.5K ﹤0.01% 7108
2023
Q1
Sell
-1,074
Closed -$14.4K 7780
2022
Q4
$14.4K Sell
1,074
-917
-46% -$11.5K ﹤0.01% 6836
2022
Q3
$27K Sell
1,991
-6,671
-77% -$87.7K ﹤0.01% 6917
2022
Q2
$99K Buy
8,662
+1,494
+21% +$16.3K ﹤0.01% 6467
2022
Q1
$96K Sell
7,168
-4,983
-41% -$72K ﹤0.01% 6886
2021
Q4
$214K Sell
12,151
-5,327
-30% -$137K ﹤0.01% 6460
2021
Q3
$555K Buy
+17,478
New +$1M ﹤0.01% 5569
2021
Q2
Sell
-14
Closed 7725
2021
Q1
$0 Buy
+14
New +$300 ﹤0.01% 7395
2020
Q2
Sell
-1,225
Closed -$4K 6810
2020
Q1
$4K Buy
+1,225
New +$6.03K ﹤0.01% 6521

Other funds holding ANVS

Bank of America's ANVS Position: Q1 2026 in Review

Bank of America sold out of Annovis Bio (ANVS) in Q1 2026, closing a stake of 207 shares — an estimated $716 sold.

Bank of America first reported a position in ANVS in Q1 2020 and held it in 19 quarters. The position peaked at $555K in Q3 2021. 56 funds tracked by Wall St. Rank hold ANVS as of Q1 2026.

  • Bank of America reported no remaining Annovis Bio position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 207 Annovis Bio shares in Q1 2026, an estimated $716.
  • Bank of America first reported a position in Annovis Bio in Q1 2020 and held it in 19 quarters.
  • Bank of America's Annovis Bio position peaked at $555K in Q3 2021.
  • 56 funds tracked by Wall St. Rank held Annovis Bio as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.